These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

934 related items for PubMed ID: 20843542

  • 21. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [Abstract] [Full Text] [Related]

  • 22. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 23. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 24. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B.
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [Abstract] [Full Text] [Related]

  • 27. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 28. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 29. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C, Manger B.
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ.
    Lancet; 2000 Jul 29; 356(9227):385-90. PubMed ID: 10972371
    [Abstract] [Full Text] [Related]

  • 40. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN.
    J Eur Acad Dermatol Venereol; 2009 Dec 29; 23(12):1394-7. PubMed ID: 19573024
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.